Keyla Milena Meneses
Research Subjects
Keyla Milena Meneses has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Hurtado-Ortiz
Fundación Cardiovascular de Colombia, Floridablanca, Santander, Colombia; Hospital Internacional de Colombia, Piedecuesta, Santander, Colombia
1 shared publication - Andrés Felipe Rubio-Duarte
Congenital and Pediatric Heart Diseases Center, Cardiovascular Institute, Hospital Internacional de Colombia HIC—Fundación Cardiovascular de Colombia FCV—Fundación Universitaria FCV, Santander, Colombia
1 shared publication - Carlos Enrique Prada
Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL
1 shared publication - Javier Castro
Fundación Cardiovascular de Colombia
1 shared publication - Jorge Luis Alvarado Socarras
Fundación Cardiovascular de Colombia
1 shared publication - José Antonio Vargas Soler
Servicio de Infectología pediátrica, Hospital Internacional de Colombia, Bucaramanga, Colombia
1 shared publication
Latest Publications
- 18 May 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (12) , 1086-1088
Severe Pneumocystis jirovecii Pneumonia as the Sentinel Presentation of BENTA Disease: Case Report of a 3-Month-old Infant
Pneumocystis jirovecii can cause severe pneumonia in HIV-negative infants with underlying immunodeficiency. We report an infant with prior acute respiratory distress syndrome and recurrent infections unresponsive to antibiotics. Persistent interstitial opacities led to immunologic testing, revealing T-cell lymphopenia and a CARD11 mutation. Respiratory polymerase chain reaction confirmed P. jirovecii . Treatment with trimethoprim–sulfamethoxazole and intravenous immunoglobulin led to recovery.
- 18 May 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (12) , 1086-1088
Severe Pneumocystis jirovecii Pneumonia as the Sentinel Presentation of BENTA Disease: Case Report of a 3-Month-old Infant
Pneumocystis jirovecii can cause severe pneumonia in HIV-negative infants with underlying immunodeficiency. We report an infant with prior acute respiratory distress syndrome and recurrent infections unresponsive to antibiotics. Persistent interstitial opacities led to immunologic testing, revealing T-cell lymphopenia and a CARD11 mutation. Respiratory polymerase chain reaction confirmed P. jirovecii . Treatment with trimethoprim–sulfamethoxazole and intravenous immunoglobulin led to recovery.
- 16 February 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (5) , 1525-1531
Everolimus for severe arrhythmias in tuberous sclerosis complex related cardiac rhabdomyomas
Intracardiac rhabdomyoma is the most common primary cardiac tumor in children. Most cases are associated with tuberous sclerosis complex (TSC). Most of them are asymptomatic in the neonate and do not require treatment. However, some develop cardiovascular symptoms such as arrhythmias, heart failure, and ventricular inflow/outflow tract obstruction in the neonatal period with early death. Many of these tumors are not candidates for surgical resection and medical management is limited. Treatment with mammalian target of rapamycin (mTOR) inhibitor is currently approved for the management of central nervous tumors and angiomyolipoma in TSC. Two patients with malignant arrhythmias related to nonsurgical multiple rhabdomyomas associated with TSC who were successfully treated with an mTOR inhibitor were described. Everolimus therapy showed significant regression of rhabdomyomas with rapid improvement of arrhythmias and heart failure prior to tumor shrinkage.
- 16 February 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (5) , 1525-1531
Everolimus for severe arrhythmias in tuberous sclerosis complex related cardiac rhabdomyomas
Intracardiac rhabdomyoma is the most common primary cardiac tumor in children. Most cases are associated with tuberous sclerosis complex (TSC). Most of them are asymptomatic in the neonate and do not require treatment. However, some develop cardiovascular symptoms such as arrhythmias, heart failure, and ventricular inflow/outflow tract obstruction in the neonatal period with early death. Many of these tumors are not candidates for surgical resection and medical management is limited. Treatment with mammalian target of rapamycin (mTOR) inhibitor is currently approved for the management of central nervous tumors and angiomyolipoma in TSC. Two patients with malignant arrhythmias related to nonsurgical multiple rhabdomyomas associated with TSC who were successfully treated with an mTOR inhibitor were described. Everolimus therapy showed significant regression of rhabdomyomas with rapid improvement of arrhythmias and heart failure prior to tumor shrinkage.